Bringing the fundamentals into focus…
Back to Spyre Therapeutics, Inc.
How Spyre Therapeutics, Inc. stacks up
SYRE · against 172 other Healthcare companies of similar size
Profitability
24/ 100
Near the bottom of its peers.
Ranked #146 of 173 · scores higher than 16% of peers
Bars: peers in each 10-point band of the profitability score18 peers with a profitability score of 20–29, including SYRE · Click a bar to see the companies
Why profitability scores 24?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on assets and return on invested capital, which are weaker than most Healthcare peers.
- a lower return on assets: weaker than 78% of peers. Return on assets: -15.3% vs peer median 1.7%
- a lower return on invested capital: weaker than 78% of peers. Return on invested capital: -16.9% vs peer median 4.7%
- Operating margin is not reported, so it is left out of the score.
Metric by metric
Position: dot = SYRE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SYRE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 168 reported | -16.9% | 10.0% | 16% | 33% | |
| Operating marginHigher is better · 164 reported | Not reported | 12.8% | — | — | 33% |
| Return on assetsHigher is better · 165 reported | -15.3% | 4.5% | 17% | 33% | |
| Return on equityHigher is better · 160 reported | -23.0% | 8.9% | 19% | Context only | |
| Gross marginHigher is better · 182 reported | 0.0% | 52.1% | 2% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by profitability score
Top 5 and the companies ranked around SYRE| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 13.9B EUR (≈$15.3B) | 99 | 78 | |
| 1 | 20.0B AUD (≈$13.2B) | 99 | 77 | |
| 3 | 548.2B INR (≈$6.6B) | 98 | 68 | |
| 3 | 170.4B THB (≈$4.8B) | 98 | 70 | |
| 5 | 4.6B USD | 97 | 65 | |
| 141 | 6.6B USD | 26 | 45 | |
| 141 | 8.5B USD | 26 | 28 | |
| 144 | 5.6B USD | 25 | 53 | |
| 144 | 14.0B USD | 25 | 31 | |
| 146 | 8.8B USD | 24 | 50 | |
| 147 | 9.0B USD | 23 | 33 | |
| 148 | 34.9B CNY (≈$4.9B) | 22 | 16 | |
| 148 | 13.7B USD | 22 | 45 | |
| 150 | 8.4B USD | 21 | 28 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score